Tags: US | Novartis | FDA

Novartis Leukemia Drug Gets Faster FDA Review

Friday, 19 February 2010 11:12 AM

Novartis AG said Friday its leukemia drug candidate Tasigna received priority review by the Food and Drug Administration.

The special designation speeds up the regulatory review process to six months from the usual 10 months.

Novartis, based in Switzerland, also makes the cancer drug Gleevec.

© Copyright 2018 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Markets
Novartis AG said Friday its leukemia drug candidate Tasigna received priority review by the Food and Drug Administration.The special designation speeds up the regulatory review process to six months from the usual 10 months.Novartis, based in Switzerland, also makes the...
US,Novartis,FDA
45
2010-12-19
Friday, 19 February 2010 11:12 AM
Newsmax Media, Inc.
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
MONEYNEWS.COM
© Newsmax Media, Inc.
All Rights Reserved